APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia

Asieris Pharmaceuticals announced that its product, APL-2301, used for the treatment of Acinetobacter baumannii infections, was approved for Phase I clinical trials in Australia.